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Abstract
Surgical resection with a tumor-free margin is the only
curative treatment for hilar cholangiocarcinoma (Klatskin
tumor). However, over half of the patients present late with
unresectable tumors. Radiotherapy using external beam
irradiation or intraluminal brachytherapy (ILBT) has been
used to treat unresectable hilar cholangiocarcinoma with
satisfactory outcome. We reported a patient with unresectable
hilar cholangiocarcinoma surviving more than 6 years after
combined external beam irradiation and ILBT.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Cholangiocarcinoma is a malignant tumor arising from either
the extra-or intra-hepatic bile duct. The histological types include
adenocarcinoma, carcinoma in situ, papillary adenocarcinoma,
mucinous adenocarcinoma, and squamous cell carcinoma[1].
Hilar cholangiocarcinoma (Klatskin tumor) is a specific disease
entity involving malignant tumors that locate in the biliary
confluence at the liver hilum. Surgical resection with an adequate
tumor-free margin is the only curative treatment[2]. The reported
medium survival after surgical resection ranges from 16 to
46 mo[3-5]. A 5-year survival rate ranging from 21% to 25%
after curative hepatectomy for hilar cholangiocarcinoma has
been reported[6,7]. However, the prognosis of most patients
with hilar cholangiocarcinoma is usually poor because of
the low resectability rate, ranging from 28% to 37%[3,4,6,8].
This can be related to their locally advanced disease with
extensive biliary and/or vascular involvement, presence of
distant metastases, and poor pre-morbid conditions precluding
a major operation. The median survival for patients with
unresectable hilar cholangiocarcinoma has been reported
to be 6-12 mo[3,4,6,9].
Among the palliative therapies for unresectable hilar
cholangiocarcinoma, radiotherapy can achieve satisfactory
local tumor control and possible survival benefit. It can be
given in the form of  external beam radiotherapy (EBRT),
intraluminal brachytherapy (ILBT), or a combination of
both. With the advancement in computerized 3D treatment
planning system, the accuracy of the delivery of EBRT to
the targeted tumor has been much improved. This technique
leads to tumor shrinkage and improves bile drainage, thus
reducing the incidence of septic complications. Likewise,
ILBT imposes a high radiation dose to the tumor volume,
bypasses the radiosensitive skin and superficial structures,
and therefore spares the surrounding normal structures from
radiation toxicity. The reported medium survival for unresectable
hilar cholangiocarcinoma is 11 mo with ILBT alone[10] and
14.5 mo with combined EBRT and ILBT[11]. Both techniques
offer satisfactory symptom palliation with minimal toxicity
and are technically feasible for most patients. However, long-
term survival beyond 5 years is very rare after radiotherapy
for unresectable cholangiocarcinoma. We reported a patient
with unresectable hilar cholangiocarcinoma surviving more
than 6 years after combined treatment by EBRT and ILBT,
and briefly reviewed the literatures of this treatment modality.
CASE REPORT
A 49-year-old gentleman presented with painless obstructive
jaundice and significant weight loss in May 1998. Liver
biochemistry showed elevated bilirubin (185 mol/L) and
alkaline phosphatase (285 IU/L) concentration. His carcino-
embryonic antigen concentration was normal. Endoscopic
retrograde cholangiopancreatography (Figure 1) showed a
Bismuth type IV stricture[12]. Contrast computed tomography
(CT) scan of the abdomen revealed enlarged lymph nodes
along the hepatoduodenal ligament (Figure 2). Subsequent
hepatic and superior mesenteric angiogram showed encasement
of the common hepatic artery and main portal vein by the
tumor. The tumor was considered unresectable and ultrasound-
guided fine needle aspiration cytology of  the hilar mass
confirmed the diagnosis of  hilar cholangiocarcinoma.
Bile duct decompression was performed by percutaneous
transhepatic biliary drainage (PTBD), and the patient received
combined EBRT and ILBT. A total of 40 Gy EBRT was
3162           ISSN 1007-9327     CN 14-1219/ R     World J Gastroenterol     May 28, 2005   Volume 11   Number 20
given to the tumor bed in 20 divided fractions, which was
followed by 10 Gy ILBT using iridium 192 (Ir192) wire. These
radio-therapeutic procedures were not associated with any
complication. A self-expandable metallic stent (Wallstent,
Boston Scientific Ltd, USA) (Figure 3) was then inserted
via the PTBD tract to bypass the stricture site, and the patency
of the metallic stent lasted for 14 mo. Subsequently he
required PTBD again when the metallic stent was blocked.
There was evidence of tumor regression on reassessment
by CT scan in the first 2 years following the treatment (Figure 4).
Subsequently there was slow disease progression with bile
duct segregation and tumor infiltration to the second part
of  the duodenum. The patient relied on long-term PTBD
for symptomatic control. Nevertheless, he has survived for
more than 6 years since the initial diagnosis was made, and
enjoyed a reasonable quality of life. He was able to work
after the radiotherapy until the most recent 2 years of his
disease course. At the time of writing the manuscript, the
patient was still alive with satisfactory general condition.
DISCUSSION
In spite of its low incidence, hilar cholangiocarcinoma is a
deadly tumor because the diagnosis is commonly not made
until the disease progresses to its advanced stage which is not
amenable to curative resection. The median survival is less
than 1 year if the tumor is unresectable[3,4,6,9]. The treatment
options for unresectable advanced hilar cholangiocarcinoma
are limited. Orthotopic liver transplantation has been proposed
to be a curative treatment modality for locally advanced hilar
tumors with no evidence of extrahepatic tumors. However, it
could be offered only to patients with locally advanced unres-
ectable tumors without widespread metastases. The reported
medial survival is 25 mo[13] and 5-year survival ranges from
30% to 87%[6,14,15]. Hassoun et al[14], achieved a high 5-year
survival of  87% by very careful patient selection including
staging laparotomy. Nonetheless, the practice of this treatment
option is largely limited by the lack of organ donors and the
potential risk of tumor recurrence following immunosup-
pressive therapy. For most patients with unresectable hilar
cholangiocarcinoma, therapeutic efforts are mainly confined
to palliation, which primarily involves relief and treatment
of cholestasis. However, no palliative treatment is of proven
value in prolonging survival.
Mortality of patients with hilar cholangiocarcinoma is
usually caused by locoregional phenomena, as a result of
liver failure secondary to bile duct obstruction, cholangitis,
and sepsis. Bile duct decompression by endoscopic or radiological
techniques is of paramount importance. This not only relieves
patients’ symptoms such as itching and cholangitis, but also
facilitates biliary access and recovery of hepatic parenchymal
function. In addition, it makes further oncological treatments
of the tumor possible[9]. In fact, ILBT is regarded to be
beneficial as it improves bile drainage in patients with hilar
cholangiocarcinoma[10]. In case of significant biliary obstruction,
prior establishment of patency of the common duct is important
for a successful delivery of ILBT. This can be achieved by
self-expandable metallic stent insertion, either percutaneously
Figure 1  Endoscopic retrograde cholangiopancreatography showing bile duct
stricture at liver hilum suggesting hilar cholangiocarcinoma.
Figure 2  Contrast CT scan showing lymph node enlargement at hepatoduodenal
ligament (black arrow).
Figure 3  Metallic stent (black arrow) inside common duct on endoscopic
retrograde cholangiopancreatography.
Figure 4  Contrast CT scan showing tumor regression after combined ILBT and
external beam irradiation.
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or endoscopically via the duodenum[16,17]. ILBT prolongs
the patency of the metallic stent, which has been reported
to range from 6 to 8 mo[9,17]. This minimizes the chance of
stent occlusion, and delays the use of external biliary drain,
which is associated with significant psychological problems
and physiological disturbances such as dehydration and
electrolyte imbalance[17]. Our patient received ILBT before
metallic stent insertion, and the patency of the stent lasted
for 14 mo after brachytherapy.
With regard to ILBT, there is no randomized controlled
study to prove its effectiveness in patients with hilar cholangi-
ocarcinoma[18]. The number of patients studied was small
in most of the series in the literature[10,11,19-23]. The medium
survival after ILBT for extrahepatic cholangiocarcinoma
has been reported to range from 4 to 13 mo[19-23]. With respect
to hilar cholangiocarcinoma per se, the reported medium
survival ranges from 11 to 14.5 mo[10,11] (Table 1). ILBT was
initially planned as a boost, as part of a treatment regimen
for patients with inoperable tumors. This treatment modality
was first reported in 1979 by Zimmon et al[24]. In that study,
the iridium wire source was placed through PTBD in four
patients. The treatment duration lasted for 24-72 h. It provides
symptomatic palliation and significant tumor control without
exacerbation of cholestasis or infective complication. It is
suggested that early ILBT after PTBD might extend palliation
of jaundice due to its effect on the limitation of tumor
extension. Ir192, with a half-life of 7 d, is the usual irradiation
source for ILBT. The wire source can be put through PTBD
or a nasobiliary catheter to reach the site of neoplastic stricture
under fluoroscopic guidance. The wire can be placed across,
parallel to or inside a stent. Au198 grains, with a shorter half-
life of 2.7 d, have also been used for ILBT. It was found that
the medical staff is better protected from radioactivity when
the Au198 sources are withdrawn after brachytherapy[25].
The optimal irradiation dose and duration of brachyt-
herapy are unknown. Our patient received a combination
of 50-Gy external irradiation. The relationship between
irradiation dosage and survival has been studied by Alden
and Mohiuddin[26]. The patients with cholangiocarcinoma
receiving high-dose combined brachytherapy and external
beam radiation of more than 55 Gy showed significantly
better survival than those who received smaller doses in
unresectable cases. Among patients who received high-dose
radiation, 48% of them experienced an extended 2-year
survival. In another study, brachytherapy was given to five
patients with Klatskin tumor for up to 5 d[27]. Two ribbons
containing Ir192 seeds were threaded into the right and left
percutaneous biliary drainage catheters in a “Y-shaped”
configuration that corresponded well to the “Y-shaped”
volume of  the Klatskin tumor. Despite all these survival
results, long-term survivors after radiation therapy for hilar
cholangiocarcinoma, as in our case, have rarely been reported.
The procedure itself is not without risk. In the absence
of any standardized protocol for brachytherapy, it is meaningless
to compare the overall morbidity in different studies. The
reported complication rate for cholangitis, which can be fatal,
ranges from 6% to 30%[11,28,29]. Complications can be classified
as those related to catheter introduction and those resulting
from irradiation. There is an increased risk of bactobilia and
bile duct perforation with either endoscopic or percutaneous
biliary tract instrumentation. The wire source is introduced
to the stricture site commonly via PTBD catheters, thus
the potential risks are hemobilia, catheter dislodgement,
superficial wound infection, liver abscess, and bile leakage.
The complications related to ILBT itself are cholangitis and
pancreatitis, as a result of blocked stent with biliary obstruction,
as well as gastrointestinal tract upset with peptic ulcer or
diarrhea[11,28].
There has been no report on the benefits of offering
EBRT in advance to ILBT or vice versa. However, EBRT
is given first in the majority of centers. This may be attributed
to its effect on tumor shrinkage that prevents cholangitis
during brachytherapy treatment. It is also questionable whether
the addition of chemotherapy is beneficial to patients with
inoperable Klatskin tumors. Basically, the use of chemotherapy
is mainly limited to clinical trials. Nomura et al[30], reported
a survival benefit in patients with unresectable extrahepatic
bile duct cancer receiving brachytherapy combined with
EBRT and repeated hepatic arterial infusion chemotherapy
when compared with those receiving brachytherapy alone.
ILBT was intensely investigated 10 years ago, but it is
still not commonly practiced nowadays. This case report
showed that palliative combined EBRT and ILBT could be
associated with long-term survival. Hence, it is worthwhile
to reconsider its potential effect on local tumor control and
possible survival benefits by proper randomized controlled
trials. Hilar cholangiocarcinoma, once labeled as a dismal
disease with poor outcome, can be associated with long-
term survival as shown in our patient. In addition to improvement
of  life expectancy, the prolonging of  symptom-free survival
is an important target of the treatment as well.
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